Halina Offner

List of Publications by Year
in descending order

163	10,403	41344	38395
papers	citations	49 h-index	95 g-index

164	164	164	8072
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tyrphostin A9 protects axons in experimental autoimmune encephalomyelitis through activation of ERKs. Life Sciences, 2022, 294, 120383.	4.3	1
2	Sex differences in EAE reveal common and distinct cellular and molecular components. Cellular Immunology, 2021, 359, 104242.	3.0	30
3	Major histocompatibility complex Class II-based therapy for stroke. Brain Circulation, 2021, 7, 37.	1.8	3
4	Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease. Frontiers in Neurology, 2021, 12, 672455.	2.4	30
5	Brief report: Enhanced DRÎ±1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice. Cellular Immunology, 2021, 370, 104439.	3.0	5
6	Microglia and astrocyte involvement in neurodegeneration and brain cancer. Journal of Neuroinflammation, 2021, 18, 298.	7.2	32
7	A Novel Partial MHC Class II Construct, DRmQ, Inhibits Central and Peripheral Inflammatory Responses to Promote Neuroprotection in Experimental Stroke. Translational Stroke Research, 2020, 11, 831-836.	4.2	19
8	Surviving the storm: Dealing with COVID-19. Cellular Immunology, 2020, 354, 104153.	3.0	4
9	Spleen participation in partial MHC class II construct neuroprotection in stroke. CNS Neuroscience and Therapeutics, 2020, 26, 663-669.	3.9	13
10	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. Metabolic Brain Disease, 2019, 34, 1705-1712.	2.9	8
11	Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE. Journal of Neuroinflammation, 2019, 16, 195.	7.2	15
12	A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury. Journal of Neuroinflammation, 2019, 16, 14.	7.2	25
13	Regulatory B cells in experimental stroke. Immunology, 2018, 154, 169-177.	4.4	29
14	Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical. Translational Stroke Research, 2018, 9, 258-266.	4.2	10
15	The splenic response to stroke: from rodents to stroke subjects. Journal of Neuroinflammation, 2018, 15, 195.	7.2	57
16	Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells. Metabolic Brain Disease, 2018, 33, 1599-1607.	2.9	29
17	Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice. Journal of Neuroimmunology, 2017, 305, 59-67.	2.3	33
18	Stroke and other cerebrovascular diseases. Neurochemistry International, 2017, 107, 1-3.	3.8	3

#	Article	IF	Citations
19	Sex-dependent treatment of chronic EAE with partial MHC class II constructs. Journal of Neuroinflammation, 2017, 14, 100.	7.2	14
20	Sex differences in regulatory cells in experimental stroke. Cellular Immunology, 2017, 318, 49-54.	3.0	34
21	DRÎ±1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury. Metabolic Brain Disease, 2017, 32, 1395-1402.	2.9	15
22	DRÎ±1-MOG-35-55 Reduces Permanent Ischemic Brain Injury. Translational Stroke Research, 2017, 8, 284-293.	4.2	25
23	Estrogen protects both sexes against EAE by promoting common regulatory cell subtypes independent of endogenous estrogen. Metabolic Brain Disease, 2017, 32, 1747-1754.	2.9	24
24	Estrogen protection against EAE modulates the microbiota and mucosal-associated regulatory cells. Journal of Neuroimmunology, 2017, 310, 51-59.	2.3	47
25	Partial MHC class II constructs as novel immunomodulatory therapy for stroke. Neurochemistry International, 2017, 107, 138-147.	3.8	17
26	Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke. Neurochemistry International, 2017, 107, 148-155.	3.8	18
27	Sex differences in the immune response to experimental stroke: Implications for translational research. Journal of Neuroscience Research, 2017, 95, 437-446.	2.9	30
28	Sex differences and the role of PPAR alpha in experimental stroke. Metabolic Brain Disease, 2016, 31, 539-547.	2.9	30
29	Loss of PPARÎ± perpetuates sex differences in stroke reflected by peripheral immune mechanisms. Metabolic Brain Disease, 2016, 31, 683-692.	2.9	8
30	Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion. Translational Stroke Research, 2016, 7, 70-78.	4.2	17
31	Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2016, 293, 45-53.	2.3	49
32	HLA-DRÎ±1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. Journal of Neuroinflammation, 2015, 12, 123.	7.2	30
33	The Role of the Spleen in Ischemic Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 186-187.	4.3	41
34	Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke. Journal of Neuroimmunology, 2015, 278, 289-298.	2.3	72
35	Role for microglia in sex differences after ischemic stroke: importance of M2. Metabolic Brain Disease, 2015, 30, 1515-1529.	2.9	46
36	IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. Journal of Neuroimmunology, 2015, 285, 129-136.	2.3	26

#	Article	IF	Citations
37	Functional Role of Regulatory Lymphocytes in Stroke. Stroke, 2015, 46, 1422-1430.	2.0	136
38	Regulatory CD8+CD122+ T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells. Metabolic Brain Disease, 2015, 30, 911-924.	2.9	46
39	Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice. Metabolic Brain Disease, 2015, 30, 1117-1127.	2.9	33
40	A novel mouse model of thromboembolic stroke. Journal of Neuroscience Methods, 2015, 256, 203-211.	2.5	39
41	PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke, 2015, 46, 2926-2934.	2.0	36
42	Preclinical Evaluation of Recombinant T Cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke. Translational Stroke Research, 2015, 6, 60-68.	4.2	28
43	Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Metabolic Brain Disease, 2015, 30, 57-65.	2.9	18
44	Adoptive transfer of immune subsets prior to MCAO does not exacerbate stroke outcome in splenectomized mice. Journal of Systems and Integrative Neuroscience, 2015, 1, 20-28.	0.6	11
45	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Frontiers in Cellular Neuroscience, 2014, 8, 228.	3.7	11
46	Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy. Frontiers in Cellular Neuroscience, 2014, 8, 284.	3.7	18
47	Modeling Immunity and Inflammation in Stroke. Stroke, 2014, 45, e181-2.	2.0	4
48	A novel HLA-DRÎ±1-MOG-35-55 construct treats experimental stroke. Metabolic Brain Disease, 2014, 29, 37-45.	2.9	25
49	Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metabolic Brain Disease, 2014, 29, 59-73.	2.9	73
50	Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke. Translational Stroke Research, 2014, 5, 612-617.	4.2	26
51	Novel Humanized Recombinant T Cell Receptor Ligands Protect the Female Brain After Experimental Stroke. Translational Stroke Research, 2014, 5, 577-585.	4.2	36
52	HLA-DRÎ±1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2014, 192, 4164-4173.	0.8	48
53	Systemic Immune Responses after Experimental Stroke. , 2014, , 153-176.		0
54	Phenotypic Changes in Immune Cell Subsets Reflect Increased Infarct Volume in Male vs. Female Mice. Translational Stroke Research, 2013, 4, 554-563.	4.2	61

#	Article	IF	Citations
55	IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metabolic Brain Disease, 2013, 28, 375-386.	2.9	129
56	PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. Journal of Neuroinflammation, 2013, 10, 111.	7.2	53
57	A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. Journal of Autoimmunity, 2013, 40, 96-110.	6.5	41
58	Partial <scp>MHC</scp> class <scp>II</scp> constructs inhibit <scp>MIF</scp>/<scp>CD</scp>74 binding and downstream effects. European Journal of Immunology, 2013, 43, 1309-1321.	2.9	54
59	PD-1 Interaction with PD-L1 but not PD-L2 on B-cells Mediates Protective Effects of Estrogen against EAE. Journal of Clinical & Cellular Immunology, 2013, 04, 143.	1.5	58
60	Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune Diseases, 2012, 2012, 1-11.	0.6	33
61	Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice. Metabolic Brain Disease, 2012, 27, 487-493.	2.9	65
62	A Novel Hypothesis: Regulatory B Lymphocytes Shape Outcome from Experimental Stroke. Translational Stroke Research, 2012, 3, 324-330.	4.2	57
63	Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17Î²â€oestradiolâ€receptorâ€positive <scp>B</scp> cells that upâ€regulate <scp>PD</scp>â€1 on <scp>CD</scp>4⁺Â<scp>F</scp>oxp3⁺ regulatory <scp>T</scp> cells. Immunology, 2012, 137, 282-293.	4.4	52
64	Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis. Metabolic Brain Disease, 2012, 27, 143-149.	2.9	6
65	Contribution of GPR30 for 1,25 dihydroxyvitamin D3 protection in EAE. Metabolic Brain Disease, 2012, 27, 29-35.	2.9	16
66	Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity. Metabolic Brain Disease, 2012, 27, 7-15.	2.9	47
67	Role of dihydrotestosterone in post-stroke peripheral immunosuppression after cerebral ischemia. Brain, Behavior, and Immunity, 2011, 25, 685-695.	4.1	20
68	RTL551 Treatment of EAE Reduces CD226 and T-bet+ CD4 T Cells in Periphery and Prevents Infiltration of T-bet+ IL-17, IFN-Î³ Producing T Cells into CNS. PLoS ONE, 2011, 6, e21868.	2.5	7
69	Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. Immunology, 2011, 132, 340-347.	4.4	48
70	RTL therapy for multiple sclerosis: A Phase I clinical study. Journal of Neuroimmunology, 2011, 231, 7-14.	2.3	37
71	CD4+FoxP3+ regulatory T-cells in cerebral ischemic stroke. Metabolic Brain Disease, 2011, 26, 87-90.	2.9	106
72	Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metabolic Brain Disease, 2011, 26, 107-113.	2.9	53

#	Article	IF	Citations
73	Recombinant T Cell Receptor Ligands Improve Outcome After Experimental Cerebral Ischemia. Translational Stroke Research, 2011, 2, 404-410.	4.2	21
74	Estrogenâ€induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. European Journal of Immunology, 2011, 41, 1165-1175.	2.9	83
75	Programmed Death-1 Pathway Limits Central Nervous System Inflammation and Neurologic Deficits in Murine Experimental Stroke. Stroke, 2011, 42, 2578-2583.	2.0	69
76	Regulatory B Cells Limit CNS Inflammation and Neurologic Deficits in Murine Experimental Stroke. Journal of Neuroscience, 2011, 31, 8556-8563.	3.6	249
77	GPR30 Forms an Integral Part of E2-Protective Pathway in Experimental Autoimmune Encephalomyelitis. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 262-274.	0.5	13
78	Recombinant TCR Ligand Reverses Clinical Signs and CNS Damage of EAE Induced by Recombinant Human MOG. Journal of NeuroImmune Pharmacology, 2010, 5, 231-239.	4.1	19
79	Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2010, 225, 52-61.	2.3	27
80	GPR30, but not estrogen receptor-Î±, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol. BMC Immunology, 2010, 11, 20.	2.2	66
81	Downâ€modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2010, 88, 7-15.	2.9	73
82	5-Androstenediol Ameliorates Pleurisy, Septic Shock, and Experimental Autoimmune Encephalomyelitis in Mice. Autoimmune Diseases, 2010, 2010, 1-8.	0.6	11
83	Estradiol and G1 Reduce Infarct Size and Improve Immunosuppression after Experimental Stroke. Journal of Immunology, 2010, 184, 4087-4094.	0.8	117
84	Characterization of human platelet binding of recombinant T cell receptor ligand. Journal of Neuroinflammation, 2010, 7, 75.	7.2	16
85	Tissue-Dependent Expression of Estrogen Receptor Î² in 17Î² -Estradiol- Mediated Attenuation of Autoimmune CNS Inflammation~!2010-04-23~!2010-06-30~!2010-07-14~!. The Open Autoimmunity Journal, 2010, 2, 197-204.	0.4	4
86	CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model. Journal of Alzheimer's Disease, 2010, 22, 619-629.	2.6	44
87	Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand. Journal of Neuroscience, 2009, 29, 3816-3823.	3.6	30
88	Recombinant T Cell Receptor Ligand Treats Experimental Stroke. Stroke, 2009, 40, 2539-2545.	2.0	78
89	An Orally Bioavailable Synthetic Analog of an Active Dehydroepiandrosterone Metabolite Reduces Established Disease in Rodent Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 1100-1109.	2.5	28
90	Oestrogen modulates experimental autoimmune encephalomyelitis and interleukinâ€17 production via programmed death 1. Immunology, 2009, 126, 329-335.	4.4	116

#	Article	IF	Citations
91	Membrane Estrogen Receptor Regulates Experimental Autoimmune Encephalomyelitis through Up-regulation of Programmed Death 1. Journal of Immunology, 2009, 182, 3294-3303.	0.8	131
92	Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?. Immunology, 2008, 125, 1-13.	4.4	37
93	IL-13-Mediated Gender Difference in Susceptibility to Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 180, 2679-2685.	0.8	47
94	MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis. Journal of Immunology, 2008, 180, 1249-1257.	0.8	21
95	Recombinant Î Cell Receptor Ligands: Immunomodulatory, Neuroprotective and Neuroregenerative Effects Suggest Application as Therapy for Multiple Sclerosis. Reviews in the Neurosciences, 2008, 19, 327-39.	2.9	18
96	GPR30 Contributes to Estrogen-Induced Thymic Atrophy. Molecular Endocrinology, 2008, 22, 636-648.	3.7	180
97	A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS. Journal of Neuroscience, 2007, 27, 12531-12539.	3.6	50
98	Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). International Immunology, 2007, 19, 337-343.	4.0	202
99	T- and B-Cell-Deficient Mice with Experimental Stroke have Reduced Lesion Size and Inflammation. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1798-1805.	4.3	341
100	Monomeric DR2/MOG-35â€“55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clinical Immunology, 2007, 123, 95-104.	3.2	19
101	Splenic Atrophy in Experimental Stroke Is Accompanied by Increased Regulatory T Cells and Circulating Macrophages. Journal of Immunology, 2006, 176, 6523-6531.	0.8	367
102	Antigen-Specific Therapy Promotes Repair of Myelin and Axonal Damage in Established EAE. Journal of Neurochemistry, 2006, 98, 1817-1827.	3.9	48
103	Experimental Stroke Induces Massive, Rapid Activation of the Peripheral Immune System. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 654-665.	4.3	483
104	A Potential Role for Estrogen in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Annals of the New York Academy of Sciences, 2006, 1089, 343-372.	3.8	90
105	Î±B-Crystallin-reactive T cells from knockout mice are not encephalitogenic. Journal of Neuroimmunology, 2006, 176, 51-62.	2.3	14
106	Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway. Journal of Neuroscience Research, 2006, 84, 370-378.	2.9	205
107	Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands. , 2006, 47, 2555.		22
108	Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. Journal of Neuroimmunology, 2005, 170, 85-92.	2.3	173

#	Article	IF	Citations
109	Decreased FOXP3 levels in multiple sclerosis patients. Journal of Neuroscience Research, 2005, 81, 45-52.	2.9	323
110	Middle-Age Male Mice Have Increased Severity of Experimental Autoimmune Encephalomyelitis and Are Unresponsive to Testosterone Therapy. Journal of Immunology, 2005, 174, 2387-2395.	0.8	78
111	Treatment of Passive Experimental Autoimmune Encephalomyelitis in SJL Mice with a Recombinant TCR Ligand Induces IL-13 and Prevents Axonal Injury. Journal of Immunology, 2005, 175, 4103-4111.	0.8	37
112	Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-Î± and IL-1Î². Clinical Immunology, 2005, 115, 162-172.	3.2	30
113	Congruent Effects of Estrogen and T-Cell Receptor Peptide Therapy on Regulatory T Cells in EAE and MS. International Reviews of Immunology, 2005, 24, 447-477.	3.3	18
114	Cutting Edge: Estrogen Drives Expansion of the CD4+CD25+ Regulatory T Cell Compartment. Journal of Immunology, 2004, 173, 2227-2230.	0.8	454
115	Monomeric Recombinant TCR Ligand Reduces Relapse Rate and Severity of Experimental Autoimmune Encephalomyelitis in SJL/J Mice through Cytokine Switch. Journal of Immunology, 2004, 172, 4556-4566.	0.8	49
116	Myelin oligodendrocyte glycoprotein-35â€“55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. European Journal of Immunology, 2004, 34, 1251-1261.	2.9	61
117	Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. Journal of Neuroscience Research, 2004, 76, 129-140.	2.9	32
118	Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2004, 77, 119-126.	2.9	46
119	T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. Journal of Neuroscience Research, 2004, 77, 670-680.	2.9	13
120	Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis. Journal of Neuroscience Research, 2004, 78, 603-624.	2.9	76
121	A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse. Clinical Immunology, 2004, 110, 181-190.	3.2	10
122	Opposing roles for TGF-Î²1 and TGF-Î²3 isoforms in experimental autoimmune encephalomyelitis. Cytokine, 2004, 25, 45-51.	3.2	28
123	T Lymphocytes Do Not Directly Mediate the Protective Effect of Estrogen on Experimental Autoimmune Encephalomyelitis. American Journal of Pathology, 2004, 165, 2069-2077.	3.8	55
124	Estrogen Receptor-1 (Esr1) and -2 (Esr2) Regulate the Severity of Clinical Experimental Allergic Encephalomyelitis in Male Mice. American Journal of Pathology, 2004, 164, 1915-1924.	3.8	36
125	Endogenous CD4+BV8S2? T cells from TG BV8S2+ donors confer complete protection against spontaneous experimental encephalomyelitis (Sp-EAE) in TCR transgenic, RAG?/? mice. Journal of Neuroscience Research, 2003, 71, 89-103.	2.9	13
126	CNS gene expression pattern associated with spontaneous experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2003, 73, 667-678.	2.9	23

#	Article	IF	Citations
127	Functional assay for human CD4⁺CD25⁺ Treg cells reveals an ageâ€dependent loss of suppressive activity. Journal of Neuroscience Research, 2003, 74, 296-308.	2.9	184
128	The Protective Effect of 17Î²-Estradiol on Experimental Autoimmune Encephalomyelitis Is Mediated through Estrogen Receptor-Î±. American Journal of Pathology, 2003, 163, 1599-1605.	3.8	167
129	Recombinant TCR Ligand Induces Early TCR Signaling and a Unique Pattern of Downstream Activation. Journal of Immunology, 2003, 171, 1934-1940.	0.8	46
130	Transfer of Severe Experimental Autoimmune Encephalomyelitis by IL-12- and IL-18-Potentiated T Cells Is Estrogen Sensitive. Journal of Immunology, 2003, 170, 4802-4809.	0.8	41
131	Oral Feeding with Ethinyl Estradiol Suppresses and Treats Experimental Autoimmune Encephalomyelitis in SJL Mice and Inhibits the Recruitment of Inflammatory Cells into the Central Nervous System. Journal of Immunology, 2003, 170, 1548-1555.	0.8	115
132	Recombinant TCR Ligand Induces Tolerance to Myelin Oligodendrocyte Glycoprotein 35-55 Peptide and Reverses Clinical and Histological Signs of Chronic Experimental Autoimmune Encephalomyelitis in HLA-DR2 Transgenic Mice. Journal of Immunology, 2003, 171, 127-133.	0.8	83
133	17Beta-estradiol treatment profoundly down-regulates gene expression in spinal cord tissue in mice protected from experimental autoimmune encephalomyelitis. Archivum Immunologiae Et Therapiae Experimentalis, 2003, 51, 185-93.	2.3	8
134	Identification of Bphs , an Autoimmune Disease Locus, as Histamine Receptor H ₁. Science, 2002, 297, 620-623.	12.6	148
135	Evaluation of the Effects of 17Î²-Estradiol (17Î²-E2) on Gene Expression in Experimental Autoimmune Encephalomyelitis Using DNA Microarray. Endocrinology, 2002, 143, 313-319.	2.8	59
136	A synthetic androstene derivative and a natural androstene metabolite inhibit relapsingâ€“remitting EAE. Journal of Neuroimmunology, 2002, 130, 128-139.	2.3	40
137	Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE. Journal of Neuroscience Research, 2002, 67, 680-688.	2.9	34
138	Estrogen inhibition of EAE involves effects on dendritic cell function. Journal of Neuroscience Research, 2002, 70, 238-248.	2.9	151
139	17?-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. Journal of Neuroscience Research, 2001, 65, 529-542.	2.9	125
140	Diminished frequency of interleukin-10-secreting, T-cell receptor peptide-reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene. Journal of Neuroscience Research, 2001, 66, 171-176.	2.9	16
141	TCR peptide therapy in human autoimmune diseases. Neurochemical Research, 2001, 26, 713-730.	3.3	43
142	Estrogen Treatment Down-Regulates TNF-Î± Production and Reduces the Severity of Experimental Autoimmune Encephalomyelitis in Cytokine Knockout Mice. Journal of Immunology, 2001, 167, 542-552.	0.8	245
143	Low-Dose Estrogen Therapy Ameliorates Experimental Autoimmune Encephalomyelitis in Two Different Inbred Mouse Strains. Journal of Immunology, 2001, 166, 2080-2089.	0.8	311
144	Rudimentary TCR Signaling Triggers Default IL-10 Secretion by Human Th1 Cells. Journal of Immunology, 2001, 167, 4386-4395.	0.8	53

#	Article	IF	Citations
145	Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops. Critical Reviews in Immunology, 2000, 20, 28.	0.5	7
146	Regulation of Encephalitogenic T Cells with Recombinant TCR Ligands. Journal of Immunology, 2000, 164, 6366-6371.	0.8	38
147	Reduced Chemokine and Chemokine Receptor Expression in Spinal Cords of TCR BV8S2 Transgenic Mice Protected Against Experimental Autoimmune Encephalomyelitis with BV8S2 Protein. Journal of Immunology, 2000, 164, 3924-3931.	0.8	34
148	Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. Journal of Clinical Investigation, 2000, 105, 1465-1472.	8.2	102
149	Treatments targeting the T cell receptor (TCR): effects of TCR peptide-specific T cells on activation, migration, and encephalitogenicity of myelin basic protein-specific T cells. Seminars in Immunopathology, 1999, 21, 77-90.	4.0	7
150	Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. Journal of Neuroscience Research, 1999, 55, 432-440.	2.9	41
151	T Cell Receptor V Genes in Multiple Sclerosis: Increased Use of TCRAV8 and TCRBV5 in MBP-Specific Clones. International Reviews of Immunology, 1999, 18, 9-36.	3.3	21
152	Immunoregulation of Encephalitogenic MBP-NAc1-11-Reactive T Cells by CD4+ TCR-Specific T Cells Involves IL-4, IL-10 and IFN-Ì³. Autoimmunity, 1999, 31, 237-248.	2.6	14
153	Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. Journal of Neuroscience Research, 1998, 52, 420-426.	2.9	68
154	Neonatal exposure of TCR BV8S2 transgenic mice to recombinant TCR BV8S2 results in reduced T cell proliferation and elevated antibody response to BV8S2, and increased severity of EAE. , 1998, 52, 750-756.		7
155	Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide. Immunology and Cell Biology, 1998, 76, 83-90.	2.3	4
156	Myelin basic crotein-specific and TCR V?8.2-Specific T-cell lines from TCR V?8.2 transgenic mice utilize the same V? and V? genes: specificity associated with the V? CDR3-J? region. Journal of Neuroscience Research, 1997, 47, 489-499.	2.9	16
157	Similar pattern of MCP-1 expression in spinal cords and eyes of Lewis rats with experimental autoimmune encephalomyelitis associated anterior uveitis. Journal of Neuroscience Research, 1997, 50, 531-538.	2.9	29
158	Similar pattern of MCP-1 expression in spinal cords and eyes of Lewis rats with experimental autoimmune encephalomyelitis associated anterior uveitis. , 1997, 50, 531.		1
159	Treatment of multiple sclerosis with Tâ€“cell receptor peptides: Results of a doubleâ€“blind pilot trial. Nature Medicine, 1996, 2, 1109-1115.	30.7	175
160	Lymphokine mRNA expression in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis is associated with a host recruited CD45R hi/CD4+ population during recovery. Journal of Neuroimmunology, 1993, 48, 105-117.	2.3	30
161	Human Cd8+ T Cell Clone Regulates Autologous Cd4+ Myelin Basic Protein Specific T Cells. Autoimmunity, 1992, 14, 111-119.	2.6	7
162	Ganglioside modulation of CD4 does not block T-helper cell function as compared to antagonism by anti-CD4 antibody. Drug Development Research, 1992, 25, 315-323.	2.9	3

#	Article	IF	Citations
163	Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature, 1989, 341, 541-544.	27.8	615